title: The value of hyoscine butylbromide in abdominal MR imaging with and without oral magnetic particles.
abstract: OBJECTIVE
  The purpose of this article was to assess the impact of intravenous (IV) anticholinergic hyoscine butylbromide in abdominal magnetic resonance (MR) imaging with oral magnetic particles (OMP) [ABDOS-CAN, Ferristene (USAN), Nycomed Imaging AS, Oslo, Norway].
  
  
  METHODS
  In 31 patients with abdominal tumors, T1-weighted spin-echo (SE) images (SE 600/ 15; 1.5 T) were obtained without and with IV hyoscine butylbromide (20 mg) before and after administration of 800 ml of OMP. Two blinded readers assessed motion artifacts, bowel-wall visualization, and lesion delineation on the four sets of T1-weighted images. The two-tailed Wilcoxon paired sample test was used for statistical analysis (p < .05).
  
  
  RESULTS
  Hyoscine butylbromide reduced motion artifacts and improved bowel-wall visualization on precontrast and OMP-enhanced images at a statistically significant level (p = 0.0006-0.037). The lowest degree of artifacts was recorded on OMP images with hyoscine butylbromide. OMP with hyoscine butylbromide significantly improved lesion delineation compared to studies without antiperistaltic drug before (p = 0.019) and after OMP administration (p = 0.01).
  
  
  CONCLUSIONS
  The authors conclude that the use of IV hyoscine butylbromide is recommended for OMP-enhanced abdominal MR imaging with T1-weighted SE pulse sequences at 1.5 T.
authors.affiliation: Department of Diagnostic Radiology, Eberhard-Karls-Universität Tübingen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Laniado
authors.forename: E
authors.initials: E
authors.lastname: Grönewäller
authors.forename: A F
authors.initials: AF
authors.lastname: Kopp
authors.forename: S F
authors.initials: SF
authors.lastname: Kaminsky
authors.forename: B
authors.initials: B
authors.lastname: Hamm
authors.forename: T F
authors.initials: TF
authors.lastname: Jacobsen
authors.forename: C D
authors.initials: CD
authors.lastname: Claussen
mesh_terms: D000008:Abdominal Neoplasms / Q000175:diagnosis*; D015746:Abdominal Pain / Q000139:chemically induced; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D016477:Artifacts; D002086:Butylscopolammonium Bromide / Q000008:administration & dosage / Q000009:adverse effects; D003287:Contrast Media / Q000009:adverse effects; D003911:Dextrans; D005260:Female; D052203:Ferrosoferric Oxide; D006801:Humans; D007089:Image Enhancement; D007275:Injections, Intravenous; D007422:Intestines / Q000473:pathology; D007501:Iron / Q000008:administration & dosage / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects; D010528:Peristalsis / Q000187:drug effects; D011446:Prospective Studies; D012449:Safety; D016037:Single-Blind Method; D013535:Suspensions; D014786:Vision Disorders / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
chemical_list: D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D018727:Muscarinic Antagonists; D010087:Oxides; D013535:Suspensions; D002086:Butylscopolammonium Bromide; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide